Impact Factor
4.73
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
22.36
19,460 total citations
h5-index
180
h5 depth signal
Cited share
67.1%
626 of 933
Total citations
19,460
Citation footprint
Metric signal
12.78
External metric anchor
Self-citation
0.9%
184 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
1,884
United Kingdom
376
China
288
Germany
257
Canada
147
Citing Fields of Research
Genetics & Genomics
1,212
Nucleic Acids Chemistry
399
Immunology
314
Noncoding RNA
265
Immunotherapy
207
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
19,685
Articles tracked across the journal lifetime
Indexed publication set
933
626 cited publications
Last 12 months
499
41.6 publications/month
Open access share
22.2%
111 OA publications in the last year
Leading citing country
United States
1,884 citing publications
Leading citing field
Genetics & Genomics
1,212 citing publications
Latest tracked publication
15 October 2026
10 recent records available
Coverage & Indexing History
v14n3,Mar. 1996-
v14n3,Mar. 1996-
Active Coverage
Research Focus & Classification
Indexed Subjects
Genetics & Genomics
Nucleic Acids Chemistry
Noncoding RNA
Immunology
Stem Cell Biology
Immunotherapy
Issuing & Sponsoring Bodies
Contributor
Nature Publishing Company
Broad Categories
Biotechnology
Genetics & Genomics
Nucleic Acids Chemistry
Immunology
Immunotherapy
Protein Structure & Folding
Medical Ethics
MeSH Descriptors
Biotechnology
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1038/s41587-026-03332-9
Open DOI
Structural variant detection across sequencing technologies
02
DOI 10.1038/s41587-026-03361-4
Open DOI
Proteomic aging clocks go to trial
03
DOI 10.1038/s41587-026-03310-1
Open DOI
In vivo engineering of CAR natural killer cells for immunotherapy using ligand-directed lipid nanoparticles
Targeted lipid nanoparticles (LNPs) offer a nonviral approach for in vivo cell engineering but efficient programming of natural killer (NK) cells remains underexplored. Here we develop NK cell-targeted LNPs (NtLNPs) using engineered bipa...
04
DOI 10.1038/s41587-026-03363-2
Open DOI
RevMed’s pancreatic cancer drug first
05
DOI 10.1038/s41587-026-03355-2
Open DOI
Engrafting human cortical organoids
06
DOI 10.1038/s41587-026-03353-4
Open DOI
Tracing the origins of CRISPR–Cas
07
DOI 10.1038/s41587-026-03337-4
Open DOI
The global patent landscape of CRISPR–Cas applications in medicine
08
DOI 10.1038/s41587-026-03349-0
Open DOI
FDA nod for rare neurology drug
09
DOI 10.1038/s41587-026-03347-2
Open DOI
Biotech news from around the world
10
DOI 10.1038/s41587-026-03338-3
Open DOI
Expanding global access to synthetic biology
Bibliographical & Catalog Notes
Title from cover.
Also issued online.
Vol. 14, no. 1 (MAR 1996)19970106 Notice not published Printed on acid-free paper that meets the full ANSI standard for Permanent Paper